LabCorp®, https://www.LabCorp.com has announced that Covance, https://www.covance.com part of their drug development business, is expanding their technology ecosystem to accelerate the adoption of decentralized clinical trials, often referred to as hybrid and virtual clinical trials.
In late 2019, Covance unveiled their latest solution to help transform how decentralized clinical trials should be conducted. The company’s decentralized clinical trials solution integrates unique capabilities from across Covance and Lab Corp.
The system provides a patient-centric ecosystem of conveniently located resources at LabCorp’s U.S. based Patient Service Centers and LabCorp at Walgreens locations, along with global partnerships with reputable retail pharmacies, as well as home health and nursing services providers, all connected by a technology platform
Covance is expanding their decentralized trials technology ecosystem through an alliance with Medable https://www.medable.com, a software provider for digital clinical trials. The Covance patient and site interface will be powered by Medable’s modular software platform, providing immediate access to applications that will allow patients to participate in decentralized clinical trials. The platform will also enable data and system interoperability, facilitate remote data collection and communication between patients, sites, and clinical investigators.
Go to https://www.covance.com/virtualtrials for more information on Covance hybrid and virtual trials.